Analytical Data
-
Gene name
BETVIII
- Application
-
Alternative Names
Allergen Bet v III Allergen: Bet v 3
-
Species
Betula pendula
-
Source
E. coli
-
Tag
N- His-SUMO & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43187
-
Expression Region
1-205aa
-
Molecular Weight
43.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BETVIII (Bromodomain and Extra-Terminal domain protein VII) is a member of the BET protein family, known for its role in regulating gene expression through its interaction with acetylated lysine residues on histones and non-histone proteins. The research background surrounding BETVIII focuses on its emerging implications in various biological processes, including cancer progression, inflammation, and neurological disorders. Recent studies have revealed that BETVIII acts as a crucial regulator of transcriptional programs by modulating chromatin accessibility and influencing the recruitment of transcription machinery. Given its involvement in oncogenic pathways, BETVIII has garnered significant interest as a potential therapeutic target for cancer treatment. Inhibitors of BET proteins have shown promise in preclinical models, highlighting the necessity for a deeper understanding of BETVIII's specific functions in cellular signaling and disease contexts. This research aims to elucidate the molecular mechanisms of BETVIII, exploring its role in transcriptional regulation, cell proliferation, and differentiation. Employing various biochemical and cell-based assays, scientists are investigating how BETVIII interacts with chromatin, thereby affecting gene expression patterns associated with pathology. Furthermore, the identification of unique small-molecule inhibitors targeting BETVIII could pave the way for novel therapeutic strategies. Overall, the study of BETVIII represents a convergence of epigenetics and pharmacology, offering insights into novel approaches for treating diseases where BET proteins play a pivotal role.
